Is It Daily, Monthly, or Yearly Blood Pressure Variability that Enhances Cardiovascular Risk?

Current Cardiology Reports

Volumn 17, Issue 11, 2015, Pages

  Dolan, Eamon ^a   O’Brien, Eoin ^b  

^a Royal College of Surgeons in Ireland   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Blood pressure variability; Cardiovascular risk; Hypertension; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ADVERSE OUTCOME; AMBULATORY BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR RISK; CLINIC BLOOD PRESSURE MEASUREMENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DAILY BLOOD PRESSURE VARIABILITY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CONTROL; HOME BLOOD PRESSURE MEASUREMENT; HUMAN; HYPERTENSION; LOW RISK POPULATION; MONTHLY BLOOD PRESSURE VARIABILITY; PATIENT COMPLIANCE; PREDICTION; PROGNOSIS; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; YEARLY BLOOD PRESSURE VARIABILITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; COMPLICATION; PATHOPHYSIOLOGY; PERIODICITY; PHYSIOLOGY; PROCEDURES; TIME FACTOR;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; PERIODICITY; RISK FACTORS; TIME FACTORS;

EID: 84941350581     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-015-0649-x     Document Type: Review

References (37)

1. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.
2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2224–60. This publication highlights the important role hypertension plays in global disease development.
3. Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension. 2007;50:991–7.
4. Turner JR, O’Brien E. Diagnosis and treatment of resistant hypertension: the critical role of ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2013;15(12):868–73.
5. Campbell NR, Sheldon T. The Canadian effort to prevent and control hypertension: can other countries adopt Canadian strategies? Curr Opin Cardiol. 2010;25:366–72.
6. O’Brien E, Dolan E, Atkins N. Failure to provide ABPM to All hypertensive patients amounts to medical ineptitude. J Clin Hypertens (Greenwich). 2015;17(6):462–5.
7. Parati G, Ochoa JE, Lombardi C, et al. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. Curr Hypertens Rep. 2015;17(4):537.
8. Dahlöf B, Sever PS, Poulter NR, ASCOT Investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895–906.
9. Poulter NR, Wedel H, Dahlöf B, ASCOT Investigators, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):907–13.
10. Williams B, Williams B, Lacy PS, CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213–25.
11. Dolan E, Stanton AV, Thom S, ASCOT Investigators, et al. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients—an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27(4):876–85.
12. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905.
13. Parati G, Ochoa JE, Lombardi C, et al. Assessment and management of blood-pressure variability. Nat Rev Cardiol. 2013;10:143–55. An excellent review of this topic by a group who have done much to advance our awareness of the importance of BPV.
14. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48.
15. Mena L, Pintos S, Queipo NV, et al. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23(3):505–11.
16. Bilo G, Giglio A, Styczkiewicz K, et al. A new method for assessing 24-h blood pressure variability after excluding the contribution of nocturnal blood pressure fall. J Hypertens. 2007;25(10):2058–66.
17. Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49(6):1265–70.
18. Stolarz-Skrzypek K, Thijs L, et al. Blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome. Hypertens Res. 2010;33(8):757–66.
19. Hansen TW, Thijs L, Li Y, Boggia J, et al. Prognostic value of reading-to-reading blood pressure variability over 24 hours in 8938 subjects from 11 populations. Hypertension. 2010;55(4):1049–57.
20. Stolarz-Skrzypek K, Thijs L, et al. Short-term blood pressure variability in relation to outcome in the International Database of Ambulatory blood pressure in relation to Cardiovascular Outcome (IDACO). Acta Cardiol. 2011;66(6):701–6.
21. Zhang Y, Agnoletti D, Safar ME, et al. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155–60. This manuscript describes the potential reduction of BPV by certain antihypertensive medications.
22. Levi-Marpillat N, Macquin-Mavier I, et al. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. Hypertens Res. 2014;37(6):585–90.
23. Matsui Y, Ishikawa J, Eguchi K, et al. Maximum value of home blood pressure: a novel indicator of target organ damage in hypertension. Hypertension. 2011;57(6):1087–93.
24. Ushigome E, Fukui M, Hamaguchi M, et al. The coefficient variation of home blood pressure is a novel factor associated with macroalbuminuria in type 2 diabetes mellitus. Hypertens Res. 2011;34(12):1271–5.
25. Hashimoto T, Kikuya M, Ohkubo T, et al. Home blood pressure level, blood pressure variability, smoking, and stroke risk in Japanese men: the Ohasama study. Am J Hypertens. 2012;25(8):883–91.
26. Johansson JK, Niiranen TJ, Puukka PJ, et al. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. Hypertension. 2012;59(2):212–8.
27. Schutte R, Thijs L, Liu YP, et al. Within-subject blood pressure level—not variability—predicts fatal and nonfatal outcomes in a general population. Hypertension. 2012;60(5):1138–47.
28. Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469–80.
29. Yokota K, Fukuda M, Matsui Y, et al. Impact of visit-to-visit variability of blood pressure on deterioration of renal function in patients with non-diabetic chronic kidney disease. Hypertens Res. 2013;36:151–7.
30. Diaz KM, Veerabhadrappa P, Kashem MA, et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res: Off J Jpn Soc Hypertens. 2012;35(1):55–61.
31. Nagai M, Hoshide S, Ishikawa J, et al. Visit-to visit blood pressure variations: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. J Hypertens. 2012;30(8):1556–63.
32. Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57(2):160–6.
33. Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women’s Health Initiative. Hypertension. 2012;60(3):625–30.
34. Mancia G, Facchetti R, Parati G, et al. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30(6):1241–51.
35. Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299–305.
36. O’Brien E, Sheridan J, O’Malley K. Dippers and non-dippers. Lancet. 1988;2(8607):397.
37. Cuspidi C, Sala C, Tadic M, et al. Non-dipping pattern and subclinical cardiac damage in untreated hypertension: a systematic review and meta-analysis of echocardiographic studies. Am J Hypertens. 2015;24.